Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data

• DOI: 10.3332/ecancer.2021.1178
• Publication Date: 2021-02-01T12:31:24Z
• Authors: Benjamín Walbaum; Francisco Acevedo; Lidia Medina; M Loreto Bravo; Tomás Merino; Mauricio Camus; Francisco Domínguez; Sebastián Mondaca; Héctor Galindo; Bruno Nervi; Carolina Ibáñez; Jorge Madrid; Sabrina Muñiz; José Peña; Érica Koch; Marcelo Garrido; Mauricio P Pinto; Cesar Sánchez
• Keywords: Carboplatin; Triple-negative breast cancer

Background: Breast cancer (BC) is the leading cause of death for Chilean women.About 11% cases are triple-negative (TN) BC.These characterised by poor prognosis, higher risk early recurrence and visceral dissemination versus other BC subtypes.Current standard treatment early-stage non-metastatic TNBC patients consists neoadjuvant chemotherapy (NACT) followed surgery radiotherapy.Pathological complete response (pCR) to NACT associated with an increase in survival rates.In general, adjuvant regimens involve similar cytotoxic drugs.Recent studies have postulated that use platinum compounds would rates.However, their effects on patient remain uncertain. Materials methods:We retrieved analysed medical records from a total 156 stage I-III female received compared rates using carboplatin (Cb)-containing non-Cb-containing at two health centres.Results: Median age was 51 years (range: 24-81); 13.5% (n = 21) Cb-containing regimens, 80.1% 125) sequential anthracyclines plus taxanes; 29.5% 46) group achieved pCR, 28% 35% 8) (p 0.59).We confirmed pCR prolonged overall survival, invasive distant disease-free (Log-rank p 0.0236).But addition Cb not differences measures 0.5216). Conclusions:To best authors' knowledge, this first report real-world data population assessing effect TNBC.The results suggest no benefit NACT.However, we confirm regardless treatment.